Gene Therapy for Sickle Cell Disease Likely Cost-Effective at <$2 Million
Incremental cost-effectiveness ratios were $126,000 and $281,000 per QALY for two simulation models from a societal perspective
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.